A
AAFP
web sites for, 63t
AAP
resources of, 61t
web sites for, 63t
ACIP, 37, 353
yellow fever vaccine recommendations, 135
Acquired immunologic defects, 8
Active immunity, 2, 10f
Active immunization
hepatitis A, 152–154
hepatitis B, 157
yellow fever, 116–126
Acute disseminated encephalomyelitis (ADEM)
inactivated mouse brain-derived Japanese
encephalitis vaccine
adverse events, 243
Acute-phase proteins, 4–5
Adaptive immune response, 2, 5
yellow fever, 106
ADEM
inactivated mouse brain-derived Japanese
encephalitis vaccine
adverse events, 243
Adenoids, 2
Adjuvants, 12
BD vaccine, 270
Adolescents
BCG vaccine, 263
AdSORbed rhesus diploid cell rabies vaccine, 202, 204t
Adverse events, 80
international perspective, 83
prevention of, 82
reporting of, 83
Advisory Committee on Immunization Practices
(ACIP), 37, 353
yellow fever vaccine recommendations, 135
Aedes aegypti mosquitoes, 100, 101, 115, 298, 303
Aedes africanus mosquitoes, 112, 114
Aedes furcifer mosquitoes, 115
Aedes luteocephalus mosquitoes, 115
Aedes vittatus mosquitoes, 115
Aeromonas
traveler’s diarrhea, 276
Afghanistan
cholera, 173
poliomyelitis, 361
Africa
cholera, 176
hepatitis A, 366
hepatitis B, 369
meningitis, 188
meningitis belt, 347
meningococcal epidemic risk areas in, 186f, 187f
poliomyelitis, 361
rabies, 203, 205
yellow fever
incidence of, 110, 110f
After-hours care
policies, 90
procedure, 90
Alcohol
meningitis, 188
Alcoholic cirrhosis, 404
Alhydrogel, 12
Allergies, 79, 80
to vaccine, 75
Allogeneic bone marrow transplantation
meningococcal polysaccharide vaccine, 192
Alum, 12
Aluminum hydroxide (alhydrogel), 12
Aluminum salts, 12
AIVAC, 247–248
Amazon basin
hepatitis B vaccine, 341
American Academy of Family Physicians (AAFP)
web sites for, 63t
American Academy of Pediatrics (AAP)
resources of, 61t
web sites for, 63t
Anaphylaxis, 82
Anatomic injection site
selection of, 71
Anergy
definition of, 5
Antipneumococcal conjugate vaccine
Avaxim, 153t
Aventis Pasteur, Inc.
web site and telephone number, 94
Australia
cholera, 174
Japanese encephalitis, 224t, 226, 241t
rabies, 206
resources of, 62t
web sites for, 63t
Autoimmune disease, 397
Avaxim, 153t
Bacillus anthracis, 394
Bacteria
subverting human defenses, 8–9
Bangladesh
Japanese encephalitis, 224t, 226
poliomyelitis, 361
rabies, 203
tuberculosis, 378
typhoid fever, 164
Bat rabies, 206
Bayer Pharmaceutical Group
web site and telephone number, 94
Biological warfare
rabies virus, 214–215
BioManguinhos (Brazil), 139
BioPort Corporation
web site and telephone number, 94
BIOVAX II, 359t
Biken vaccine, 219, 237, 238, 240
efficacy of, 242–243
Bio-Hep-B, 153t
Bipolar disorder
tuberculosis, 378
Biomedical laboratory tests
rabies virus, 214–215
Biological warfare
rabies virus, 214–215
Biologic warfare
rabies virus, 214–215
BioManguinhos (Brazil), 139
BioPort Corporation
web site and telephone number, 94

Index
TRAVELERS’ VACCINES

Cytokine-secreting cells
double-ended antibodies, 30f
Cytokine secretion assays, 29
Czech Republic
tenorrhitis, 188

D
Dapsone-pyrimethamine (Maloprim)
effect on vaccine efficacy, 41t
Databases
commercially available travel health, 39
Day care centers
hepatitis A, 152
DDA, 270
DEN-2 16681 PDK53, 299
Denmark
Dengue shock syndrome (DSS), 298
Dengue hemorrhagic fever (DHF), 298
DEN-2, 16681 PDK53, 299

Deoxyribonucleic acid (DNA)

Demographic data, 79
Dengue, 221t
Dengue 2
dengue fever vaccines, 302
Dengue 4, 302–303
Dengue fever vaccines, 298–307
chimeric vaccines, 301–302
in development, 299–306
DNA, 305–306
inactivated or subunit vaccines, 303–304
live attenuated viruses, 299–300
molecularly attenuated viruses, 302–303
recombinant subunit, 304
safety issues with, 300
synthetic peptide, 304–305
tissue culture-based, 303–304
Dengue hemorrhagic fever (DHF), 298
Dengue shock syndrome (DSS), 298
Denmark
inactivated mouse brain-derived Japanese encephalitis vaccine, 243
meningitis, 188
DEN-2 16681 PDK53, 299
Deoxyribonucleic acid (DNA)
dengue fever vaccines, 305–306
Deoxyribonucleic acid (DNA) vaccine
Deoxyribonucleic acid (DNA), 13, 17–18
BCG, 269
Japanese encephalitis, 248
Documentation, 29
Double-ended antibodies
cytokine-secreting cells, 30f
Doxycycline
effect on vaccine efficacy, 41t
D2-PIV, 303–304
DPT. See Diphtheria (DPT)
Drug abusers
hepatitis A, 152
hepatitis B, 157
DSS, 298
DTaP. See Diphtheria and tetanus toxoids and acellular pertussis (DTaP)
Duck embryo rabies vaccine, 202
Dukoral, 176
Dysentery, 283

F
Ear piercing
hepatitis B, 158
Economic evaluation, 422–423
Egg allergies
pediatric travelers, 350
Egg protein, 75
allergic reaction to, 129–130
Egypt
poliomyelitis, 361
Tyr21a, 165
Elderly
Japanese encephalitis, 226
yellow fever vaccine, 136
ELISA. See Enzyme-linked immunosorbent assay (ELISA)
ELISPOT, 22, 29
Emergency equipment and training, 58
Emergency preparedness, 82
Encephalitis
following yellow fever vaccination, 121
yellow fever vaccine, 137
End stage renal disease (ESRD), 403–404
Energix B, 153t, 371t
England
rabies, 206
Entamoeba histolytica
traveler’s diarrhea, 276
Enteric vaccines
immunologic considerations, 277–278
Enterotoxigenic Escherichia coli (ETEC), 279–282
live attenuated vaccines, 281
subunit vaccines, 281–282
transcutaneous immunization, 282
vaccines in clinical development, 290t

Enterovirus, 151
Environmental (nontuberculous) mycobacteria, 262
Enterovirus vaccine
immunologic considerations, 277–278
Enterotoxigenic Escherichia coli (ETEC), 279–282
live attenuated vaccines, 281
subunit vaccines, 281–282
transcutaneous immunization, 282
vaccines in clinical development, 290t

Expatriates
hepatitis A, 152
hepatitis B, 158

F
Faget’s sign, 102
Fetal bovine kidney cell rabies vaccine, 202
Flaccid paralysis
with Japanese encephalitis, 230
Flaviviruses, 101, 220–222
medically important, 221t
structure and replication strategy of, 221–222
FluMist, 373
Fluoroquinolones
children, 192
with meningooccal vaccine, 192, 192t
pregnancy, 192
Food-borne outbreaks
of hepatitis A, 151
Food handlers
hepatitis A, 152
Foreign students, 353–383
Formalin inactivated mouse brain derived vaccine, 219
France
hepatitis B, 157
malaria, 313
rabies, 201, 205
Functional antibody tests, 25–29

G
Gambia
meningitis, 186
GAVI
web sites for, 63t
Genetic defects, 7–8
GenHevac B, 153t
German measles. See Rubella (German measles)
vaccine
Germany
meningitis, 188
rabies, 201, 205
Ghana
meningitis, 186
Giardia
Inactivated polio vaccine (IPV)
Inactivated poliovirus vaccine (IPV)
- minimum ages and intervals between, 333t
Inactivated (killed) vaccines, 14
- immunosuppression, 349–350
India
- BCG vaccine, 260, 262
- cholera, 173
- Japanese encephalitis, 224t, 226, 227, 241t
- meningitis, 186
- meningitis belt, 347
- poliomyelitis, 361
- rabies, 203, 205
- tuberculosis, 378
- typhoid fever, 163–164
- virus, 17
- yellow fever, 108
Indonesia
- Japanese encephalitis, 224t, 228
- tuberculosis, 378
Infant rat meningitis passive protection assay, 28–29
Infants. See also Pediatric travelers
- meningococcal vaccines, 193
- yellow fever vaccine, 135–136
Infection control, 57, 68–69
Infectious disease
- economic aspects of, 420–422
Influenza vaccines, 11, 373t
- allergy to, 75
- college students, 370–373
- egg allergies, 350
- immunocompromised, 389
- minimum ages and intervals between, 333t
- multiple sclerosis, 396
- pregnancy, 389, 400
Influenza virus, 17
- Information sources
- assessment criteria for, 37t
- Information systems, 36
- Informed consent, 80
- international perspective, 66
- Injection
- international perspective of, 75
- needle placement for, 71f
- Injection equipment
- selection of, 71
- Innate (natural) response, 2, 3
- Interferon
- for Japanese encephalitis, 235
- type I
- 17D vaccine, 124
- yellow fever, 106
- Interferon-alpha
- for Japanese encephalitis, 232
- Interferon-gamma
- yellow fever, 106
International Certificate of Vaccination
- World Health Organization (WHO), 80–81
International Health Regulations
- requirements outside of, 35–36
- revisions for, 34–35
- World Health Organization (WHO), 32–35
International students
- vaccines, 356
International Travel and Health (Blue Book)
- World Health Organization (WHO)
- ordering information, 130
- web site, 38
- International Union Against Tuberculosis and Lung Disease (IUATLD), 261
- Intestinal infectious disease, 419
- Intradermal injection, 72
- administration of
- policy and procedure, 91
- Intramuscular injection, 72
- administration of, 73f
- IPV
- injectable (Salk), 340
- minimum ages and intervals between, 333t
- Iran
- rabies, 205
- Ireland
- measles, 345
- Israeli military recruits
- Shigella vaccines, 286
- Italy
- hepatitis A, 366
- hepatitis B, 157
- Itinerary
- identification of, 42
- risk points in, 43–44
- ITP, 403
- IUATLD, 261
- Ivory Coast
- cholera, 173
- J
- Jamborees
- meningitis, 188
- Japan
- inactivated mouse brain-derived Japanese encephalitis vaccine, 243
- Japanese encephalitis, 224t, 241t
- Japanese B encephalitis
- immunocompromised, 391
- pregnancy, 391, 401
- risk, 414–415
- Japanese encephalitis, 221t
- clinical features of, 229–232
- diagnosis of, 232
- distribution of, 220f
- elderly, 226
- epidemic vs. endemic disease, 226–227
- epidemiology of, 227–229
- heterologous antiflavivirus antibodies, 236
- high-risk countries
- vaccination policies of, 241t
- histopathology of, 235
- immune response, 235–236
- incidence of, 227–228
- infectious agent for, 220–222
- management of, 232–236
- nonvaccine preventive measures, 236
- outcome of, 233f
- pathogenesis of, 234
- risk by country, 245–247
- risk points in, 43–44
- sequelae of, 233f
- transmission cycle of, 223f
- yellow fever, 104
- Japanese encephalitis vaccine, 237t
- K
- Kenya
- tuberculosis, 378
- Kidneys
- yellow fever, 105
- Killed vaccines, 14
- immunosuppression, 349–350
- Korea
- Japanese encephalitis, 224t
- Kupffer’s cells
- yellow fever, 104
- Kyasanur forest disease virus, 221t
- L
- Lactation
- mimicking yellow fever, 107
- Leukocytes, 2
- Lipopolysaccharide (LOS), 29
- Lipopolysaccharides
- meningitis, 189
- Listeria monocytogenes, 9
- Live attenuated SA14-14-2 vaccine, 245–247
- Live attenuated (disabled) vaccines, 14
- Japanese encephalitis, 237t
- Liver
- yellow fever, 104f
- Liver disease
- hepatitis A, 152
- Live-virus vaccines
- immunosuppression, 349–350
- LOS, 29
- Louse-borne relapsing fever
- mimicking yellow fever, 107
- Lupus erythematosus, 403
- Lymph nodes, 2
- yellow fever, 105
- Lymphoid cells, 3
- Lymphoid system, 2, 2f
- M
- Madagascar
- cholera, 173
- efficacy, 413t
- historic perspective, 219–222
- inactivated cell culture-derived, 244–245
- live attenuated SA14-14-2 vaccine, 245–247
- Japanese encephalitis virus (JEV)
- epidemiology of, 223–229
- enzootic cycle, 223
- geographic distribution, 223–224
- prototypes and genotypes of, 222
- transmission cycle of, 223f
- Jenner, Edward, 1
- JEV. See Japanese encephalitis virus (JEV)
Nigeria
 meningitis, 185
 poliomyelitis, 361
 tuberculosis, 378
 NK cells, 3, 5
 yellow fever, 106

NOMV vaccine
 meningitis, 194

Nonparenteral vaccines
 administration of, 68–69
 oral and nasal routes, 69

Nonsteroidal anti-inflammatory drugs (NSAID)
 for Japanese encephalitis, 232
 Nontuberculous mycobacteria (NTM), 262
 North Korea
 Japanese encephalitis, 2411
 Norway
 meningitis, 188, 194
 NSAID
 for Japanese encephalitis, 232
 NTM, 262
 NYVAC, 247–248
 O
 Occupational Health and Safety (OSHA)
 blood-borne pathogen standard, 57
 web sites for, 64t
 OMP, 29
 meningitis, 189
 Omsk hemorrhagic fever, 221t
 OMV vaccine, 16, 28
 meningitis, 194
 Opacity-associated proteins
 meningitis, 189
 Opishtomonos
 with Japanese encephalitis, 229–230, 230f
 OPSI, 403
 Opsonic activity
 avidity, 24
 Opsonins, 4, 26
 Opsonophagocytosis, 25–26
 assay, 22, 24f, 26
 OPV, 340, 361–362
 Oral killed whole cell-B subunit cholera vaccine
 (rBS-WC), 174t, 176–177
 Oral poliovirus vaccine (OPV), 340, 361–362
 Organ donations
 yellow fever 17D vaccine, 137
 Oromchol, 174
 OSHA
 blood-borne pathogen standard, 57
 web sites for, 64t
 O-specific polysaccharide-protein conjugate vaccine
 Shigella, 285
 Outer membrane proteins (OMP), 29
 meningitis, 189
 Outer membrane vesicle (OMV) vaccine, 16, 28
 meningitis, 194
 Overwhelming postsplenectomy infection (OPSI), 403
 P
 Pain control, 69
 Pakistan
 Japanese encephalitis, 225t
 poliomyelitis, 361
 rabies, 203
 typhoid fever, 164
 Papua New Guinea
 Japanese encephalitis, 225t
 Parenteral vaccines
 administration of, 68–69, 69–70
 routes for, 71–75, 71f
 Parenteral whole cell typhoid vaccine, 164
 Parenteral whole cell vaccine
 cholera vaccines, 173–174
 Parkinson’s disease
 with Japanese encephalitis, 229–230
 Passive and passive-active immunization
 yellow fever, 138–139
 Passive hemagglutination test, 28
 Passive immunity, 13
 Passive immunization
 hepatitis A, 151–152
 hepatitis B, 156–157
 rabies vaccine, 205–206
 Pasteur, Louis, 200
 PATH (Program for Appropriate Technology in Health)
 web sites for, 58, 64t
 Patients
 safety of, 56–57
 vaccination records of, 81
 Paying
 willingness to, 425
 PCV
 minimum ages and intervals between, 333t
 Pediatric travelers, 332–335
 adoptees, 348–349
 BCG vaccine, 283
 CVD 103-HgR, 176
 fluoroquinolones, 192
 hepatitis B, 157, 158
 hepatitis B vaccine, 341–342
 hypersensitivity, 350
 immigrants, 348–349
 immunosuppression, 349–350
 meningitis, 188
 meningococcal meningitis vaccines, 346–347
 migrants, 348–349
 mumps vaccine, 345
 pertussis vaccine, 338–339
 pneumococcal vaccines, 346
 poliomyelitis vaccine, 339–344
 positioning for vaccination, 69
 preexposure rabies vaccination, 214–215
 rabies, 208–209
 rubella vaccine, 345
 tetanus vaccine, 338
 Ty21a (Vivotif Berna vaccine), 168
 varicella (chickenpox) vaccine, 346
 Vi capsular polysaccharide, 170
 Pediatric travelers vaccine, 335–348
 diphtheria, 335–337
 immune responses to, 335
 Penicillin, 13
 People’s Republic of China
 Japanese encephalitis, 225t
 PEPline, 383
 Personal protective equipment (PPE)
 health sciences student rotations, 383
 Pertussis
 institutional prematriculation immunization, 355t
 Pertussis vaccine, 390
 Peru
 poliomyelitis, 361
 Peru-15, 278–279
 Pestivirus, 220
 Petechial hemorrhage
 yellow fever, 105
 Peyer’s patches, 2
 Phagocytosis, 25–26
 Pharmaceutical company
 telephone numbers, 94
 web sites, 94
 Phenyleketonuria
 CVD 103-HgR, 176
 Philippines
 cholera, 174, 176
 Japanese encephalitis, 225t, 226
 tuberculosis, 378
 typhoid fever, 164
 PHKC rabies vaccine, 202, 204t
 Pflin, 27
 Plague vaccine, 394
 Plesiomonas
 traveler’s diarrhea, 276
 Pneumococcal capsular vaccine, 15
 Pneumococcal conjugate vaccine (PCV)
 minimum ages and intervals between, 333t
 Pneumococcal disease, 16–17
 Pneumococcal disease vaccine, 378t
 immunocompromised, 389
 pregnancy, 389
 Pneumococcal infection
 college students, 376–378
 Pneumococcal polysaccharide vaccine (PPV), 377
 minimum ages and intervals between, 333t
 Pneumocystis carinii, 4, 7
 Policies, 49–50
 after-hours care, 90
 intradermal injection
 administration of, 91
 postimmunization anaphylaxis, 97–99
 vaccine refrigerator, 88
 Poliomyelitis
 eradication progress, 339f
 Poliomyelitis-like acute flaccid paralysis
 with Japanese encephalitis, 231f
 Poliomyelitis vaccine, 363t
 college students, 361–362
 HIV, 398–399
 immunocompromised, 390
 in postsecondary schools, 354f
 pregnancy, 390, 402
 Polysaccharide conjugate vaccines, 16–17
 Polysaccharide vaccines
 immunosuppression, 349–350
 meningitis, 191–193
 PorA OMV vaccine, 194
 Polio
 meningitis, 189
 Portal hypertension, 403
 Post-exposure prophylaxis
 in postsecondary schools, 354f
 Post-exposure prophylaxis Hotline (PEPline), 383
 Postexposure prophylaxis
 contraindications to, 211
 failure of, 212
 schedules, 210t
 Postimmunization anaphylaxis
 policies and procedures, 97–99
Rabies

Quarantinable disease

Purified Vero cell rabies vaccine, 203, 204t
Purified polysaccharide vaccines, 15
Purified duck embryo rabies vaccine, 202, 204t
Purified, inactivated DEN-2 vaccine (D2-PIV), 303–304
Purified chick embryo cell rabies vaccine, 203, 204t
Purified duck embryo rabies vaccine, 202, 204t
Purified polysaccharide vaccines, 15
Purified protein derivative (PPD), 5
Purified Vero cell rabies vaccine, 203, 204t

Preexposure rabies vaccination, 207–209
Rabies-free countries, 207t
Rabies immunoglobulin (RIG), 205–206
Rabies patients management of, 212–214
Rabies vaccine, 200–215
adverse effects of, 210–211
currently available, 204t
future of, 214–215
history of, 200
immunocompromised, 393
modern, 201–204
passive immunization, 205–206
pregnancy, 393, 401
Rabies virus
biologic warfare, 214–215
Radioimmunossay (RIA), 28
Rave concerts
meningitis, 188
rBS-WC, 174t, 176–177, 280
Recombinant B subunit cholera vaccine (rBS-WC), 174t, 176–177, 280
Recombinant hemagglutinin (rHA), 17
Recombinant vaccines, 17
Japanese encephalitis, 237t
Recombinavax, 153t
Recombivax HB, 371t
Recommended vaccinations, 36–38
compiling list of, 40–46
Record keeping, 79
Refrigerator–freezer thermometers, 51
Refusal forms, 66
Renal failure, 403–404
Replication deficient canarypox, 247–248
Republic of Ireland
meningitis, 188
Required vaccines, 32–36
RES, 2, 2f, 3
Reticuloendothelial system (RES), 2, 2f, 3
rHA, 17
Rhabdomyolysis, 128
Rheumatoid arthritis, 397, 403
Rheumatoid disease, 41
RIA, 28
Ribonucleic acid (RNA) vaccines, 18
Rice-water stools
cholera, 171
Rifampin
with meningococcal vaccine, 192, 192t
RIG, 205–206
Risks
communication about, 59–67
RNA vaccines, 18
Rose spots, 163
RTS, S/SAS02A, 320
Rubella (German measles) vaccine, 26–27, 359t
college students, 360–361
in postsecondary schools, 354f
Rubelova. See Measles (Rubelova)
Russia
Japanese encephalitis, 225t

S
SA14-14-2, 237
Safe Injection Global Network
web site, 58
Safety
of patients, 56–57
Saipan
Japanese encephalitis, 226
Salicylates
for Japanese encephalitis, 232
Salik inactivated polio vaccine (IPV), 340
Salmonella, 419
adhesion, 27
traveler’s diarrhea, 275–276
Salmonella enterica, 14
Salmonella enterica serovar Typhi (Salmonella typhi), 162, 163
Saudi Arabia, 35
meningitis, 186, 187, 188
meningitis belt, 347
SBA, 22, 28
SBL Vaccin AB, 280
SCG02, 284
SC5700, 283–284
SCLAVO
adverse reactions to, 211
Screening
international perspective, 67–68
Secretary (s) IA, 26
Seizures
with Japanese encephalitis, 229
Semple vaccine (SV), 200, 201, 203–204
Senegal
meningitis, 186
meningitis belt, 347
Sequella Global TB Foundation, 271
Serum bactericidal assay (SBA), 22, 28
Serum sickness, 13–14
predicting, 211
Serum sickness syndrome
17D vaccine, 129
Serum vibriocidal antibody response, 172
Severe combined immunodeficiency, 7
Sewage workers
hepatitis A, 152
Shigella, 17
live attenuated vaccines, 283–287
proteosome intranasal vaccine delivery, 287
subunit vaccines, 285–287
traveler’s diarrhea, 275–276, 282–287
vaccines in clinical development, 290t
Shigella conjugate vaccine, 277
Shigella flexneri, 282–283
Shigella sonnet, 282–283
Shigellosis, 283
SIADH
with Japanese encephalitis, 231f
Sickle cell anemia, 403
SIGN (Safe Injection Global Network)
web site, 58
Singapore
Japanese encephalitis, 225t
Site
abcess, 83
Skin
evaluation and preparation of, 70–71
Skin test
predicting serum sickness, 211
SLE, 397
Sleeping sickness, 219–220
Slovakia
meningitis, 188
Smallpox, 1
global eradication of, 33
Smallpox vaccine
immunocompromised, 394
pregnancy, 394
TRAVELERS’ VACCINES

South America
- South America
- South Africa
- Somalia
- South America
  - hepatitis B, 369
  - rabies, 204, 205, 209
  - yellow fever
  - incidence of, 110, 110f
- Southeast Asia
- St. Louis encephalitis, 221t

Soviet Union

Southeast Asia

Spain

Staff safety, 56–57

Subcutaneous injection, 72

Streptococcus pneumoniae

Sub-Saharan Africa

Subunit vaccines

Systemic lupus erythematosus (SLE), 397

T
- Taiwan
  - Japanese encephalitis, 226, 228, 241t

Tattoos
- hepatitis B, 158
- TBVIAc, 271
- CD4+11
- TCP, 172
- Tembusu viruses, 236
- Thalassemia, 403
- T helper cells type 1 class (Th1), 6, 22
- T helper cells type 2 class (Th2), 22
- Thymus, 3
- Tick-borne encephalitis, 221t
- Tick-borne encephalitis vaccine, 394
- Tick-borne viruses, 221t
- Time, 425
- Tissue culture-derived vaccines, 15
- T lymphocytes, 3
- 17D vaccine, 124
- TNF-α
- 17D vaccine, 124
- Tonsils, 2
- Toxin-coregulated pili (TCP), 172
- Toxoid vaccines, 14
- Transferrin-binding protein B vaccine, 194–195
- Travax subscription database, 39
- Travel-associated infection
  - vaccination for
  - modeling impact of, 427–428
- Travelers
  - current health status
  - determination of, 40
  - current vaccine status
  - determination of, 40
  - medication use
  - determination of, 42–43
- Traveler’s diarrhea
  - epidemiology of, 275–277
  - Shigella, 282–287
- Travel health clinic
  - immunization policies and procedures for, 92–93
- Travel-related infections, 419–420
- Travel-related syndromes
  - differential diagnosis of, 39
- Trip data, 79
- Tuberculin skin testing, 265–266
- health sciences student rotations, 383
- Tuberculosis, 5, 257
- college students, 378–380

incidence of, 348t
- screening
  - in postsecondary schools, 354f

Tuberculosis vaccine
- See also Bacille Calmette-Guérin (BCG) vaccine
- adverse effects of, 259
- candidates, 268–270
- constraints to, 271–272
- future developments of, 266–267
- history of, 258–259
- in preclinical development, 268t
- safety of, 259
- types of, 266
- Tuberculosis Vaccine Initiative Advisory Committee (TBVIAc), 271
- Tumor necrosis factor-alpha (TNF-alpha)
  - 17D vaccine, 124

Turkey
- hepatitis A, 366
- Twinrix, 153f, 371t

Ty800, 171
- Ty21a (Vivotif Berna vaccine), 165–168, 165t
- antibiotics, 167
- characteristics of, 165–166
- children, 168
- contraindications for, 167
- CVD 103-HgR, 168
- dose/boost, 166–167
- efficacy and time to protection of, 167
- interactions with, 167–168
- mechanism of action, 166f
- mefloquine, 167
- pregnancy, 167
- side effects of, 167

Type B encephalitis, 219
- Type 1 interferon
  - 17D vaccine, 124
  - yellow fever, 106

Typhim Vi, 169
- Typhoid fever, 162–163
- global distribution of, 164f
- risks, 163–164

Typhoid fever vaccines, 162–171
- currently available, 164–170, 165t
- economic evaluation of, 426
- efficacy, 413
- HIV, 399
- immunocompromised, 392
- new general live oral, 170
- new parenteral, 171
- pregnancy, 392, 401
- previously available, 164
- risk, 412

U
- Uganda
  - tuberculosis, 378

United Kingdom (UK)
- BCG vaccine, 260
- inactivated mouse brain-derived Japanese
  - encephalitis vaccine
- adverse events, 243
- malaria, 313
- meningitis, 188
- Meningococcal Carriage Group, 193
- National Health Service (NHS), 422–423

United Nations
- Expanded Program for Immunization (EPI), 1
United Nations International Children’s Emergency Fund (UNICEF), 38
web sites for, 64t
United Republic of Tanzania tuberculosis, 378
University dormitories. See College students
University of Rochester (New York)
health sciences student rotations, 382–383
University of Washington health sciences student rotations, 383
US Army soldiers
DEN-2 16681 PDK53, 299
US Preventive Health Service guidelines for management of occupational exposure to HBV, HCV, HIV, 57
postexposure prophylaxis, 57
US Public Health Service (USPHS) web sites for, 64t

V
VAAE
Canada, 410
Vaccination adverse effects of surveillance systems for, 410
anatomic sites for limited, 78
contraindications to misconceptions concerning, 96
definition of, 1
immunologic principles of, 1–19
inadequate documentation of, 76
long-term protection of, 9–14
minimum ages and intervals between, 333t–334t
safety of communication of risk about, 411–415
Vaccination records of patients, 81
Vaccine(s) administration of equipment and supplies checklist, 95
patient encounter, 59–78
post encounter considerations, 79–83
pre-encounter quality elements, 49–50
resources for, 58–59, 60t–62t
supplies and equipment, 56
technical aspects of, 48–84
web sites for, 63t–64t
allergies to, 75
altering volume of, 78
anticipating shortages of, 56
in clinical development for diarrhea prevention, 290t
contraindications, 67
dosing schedule interruption of, 76
effectiveness of, 11–12
efficacy of, 423–424
inspection and reconstitution of, 69–70
interchangeability of, 77
inventory log form sample of, 54f
multiple doses of inadequate time interval for, 76
multiple injections simultaneous administration of, 77
postadministration complications, 81–83
precautions, 67
requirements and recommendations for, 32–46
risk-benefit ratio, 44–46
safety of, 409–411, 411
selection of, 40t
storage of, 53–55
transport of, 50–51, 55
wastage of, 55
Vaccine Adverse Event Reporting System (VAERS), 83, 357, 410
17D vaccine, 130
web sites for, 64t
yellow fever vaccine-associated neurotropic disease (YEL-AND), 127
Vaccine Associated Adverse Event (VAAE) Canada, 410
Vaccine information statements (VIS), 65–66, 80
Vaccine-preventable disease magnitude of threat, 44
web sites, 39
Vaccine program evaluation of, 423–425
Vaccine refrigerator policies, 88
procedure, 88–89
Vaccine refrigerator-freezer unit, 51
Vaccine supplies receipt of, 53
Vaccine temperature control monitoring of, 51–53
sample of, 52f
Vaccinia vaccine
Japanese encephalitis, 247–248
pregnancy, 402
Vaccinomics malaria, 325, 326f
VAERS. See Vaccine Adverse Event Reporting System (VAERS)
VAQTA, 153t, 368t
Varicella vaccine, 381t
college students, 356, 380–382
HIV, 398
institutional prematriculation immunization, 35t
minimum ages and intervals between, 333t
in postsecondary schools, 334f
pregnancy, 390, 402
Varicella-zoster virus (VZV), 380
Vasovagal reaction, 82–83
Varicella-zoster virus (VZV), 380
vasovagal reaction, 82–83
ViATIM, 169
Varicella-zoster virus (VZV), 380
湾州黄热病, 165–166. See also Tu21a
(Virotif Berna vaccine)
Von Ebner's esophagitis lathargica, 219–220
VZV, 380
W
Waivers, 66, 80
Web sites, 36–38, 63t–64t, 94
Western Europe hepatitis B, 157
Western Pacific Japanese encephalitis, 225t
West Nile virus, 34, 221t, 232
White cells (leukocytes), 2
Whole cell-B subunit cholera vaccine (rBS-WC), 174t, 176–177
Wild-type yellow fever protection against, 124
World Health Organization (WHO), 1
Expanded Programme on Immunization (EPI), 50
Global Forum on TB Vaccine Research and Development, 271
International Certificate of Vaccination, 80–81
International Health Regulations, 32–35
International Travel and Health (Blue Book) ordering information, 130
web site, 38
resources of, 62t
web sites for, 64t
WRSS1, 284
Wyeth Lederle Vaccines web site and telephone number, 94

X
X4073, 171
X-linked agammaglobulinemia, 7

Y
Yellow fever, 111–112, 111t, 221t
active immunization, 116–126
countries requiring vaccination certificates, 135f
diagnosis of, 107–108
disease syndrome, 102–108
dominant zone, 109f
epidemiology of, 108–116
host factors, 107
iceberg phenomenon, 102f
immune response, 106–107
incidence of, 110, 110f
International Health Regulations, 33–34
irregular requirement for vaccination against, 35
liver, 104f
passive and passive-active immunization, 138–139
pathology and pathogenesis, 103–106
travelers, 111–112, 111t
treatment of, 108–109
zone of emergence, 115
Yellow fever 17D vaccine, 100–101, 104
adverse events, 126–127
rare, 127–130
with chloroquine, 138
clinical trials of, 116
cytokine responses, 124
egg protein
allergic reaction to, 129–130
manufacturers of, 116, 117
simultaneous and combined vaccination, 137–138
viremia following, 121–122
Yellow fever vaccine, 34, 100–140. See also specific vaccines
allergy to, 75
antigenic properties of, 119–120
contraindications to, 135–137
dose and route of administration, 120
efficacy, 413
egg allergies, 350
egg protein
allergic reaction to, 129–130
future, 139
HIV, 137, 398
immune response to, 122–123
kinetics of, 123
immunocompromised, 392–393
immunosuppression, 137
improper handling of, 130
indications for, 130–135
lactation, 136–137
minimum age for vaccination, 135–137
pregnancy, 136–137, 392–393, 401–402
primary failure, 125–126
with prior Flavivirus immunity, 123–124
public health policy, 140
revaccination, 123
risk, 414
safety of, 126–138
thermostability of, 120–121
in vivo genetic stability, 121
YF-VAX, 120, 122
adverse events, 126–127
allergic reactions, 130
Yellow fever vaccine-associated neurotropic disease (YEL-AND), 127–128, 414
Yellow fever vaccine-associated viscerotropic disease (YF-VAX), 120, 122
adverse events, 128–129, 131–134
Yellow fever virus
cell pathology of, 101
dengue fever vaccines, 301–302
genome organization of, 118
replication of, 101
transmission cycles, 112–116, 114
vaccination timing
algorithm for, 113
YF-VAX, 120, 122
adverse events, 126–127
allergic reactions, 130
Z
ZH9, 171
Zimbabwe
tuberculosis, 378